Central Nervous System (CNS) Disorders

Otsuka’s commitment to providing innovative solutions for central nervous system (CNS) disorders began more than 30 years ago when our researchers took the first steps in the creation of a drug that would eventually provide a new treatment option for millions of sufferers of schizophrenia and bipolar disorder.

Today, we are also focusing our energy on other important areas that include Alzheimer’s disease, Parkinson’s disease, ADHD, autism, and major depressive disorder (MDD).

Otsuka is working in a long-term alliance with Lundbeck, a Danish pharmaceutical company that also has extensive experience in developing drugs for mental health disorders. While creating new products, we put emphasis on providing robust evidence to regulatory authorities showing that any new drugs offer an improvement on what has gone before and that they represent good value in terms of improving patient outcomes.

Otsuka strives to be innovative when it comes to educating the stakeholders in the management of mental health disorders. We like to use the phrase ‘beyond the pill’, meaning that we see medication as being just one part of the total care package that we offer to help people cope with the debilitating effects of mental health disorders.

At Otsuka, the health and wellbeing of patients is our primary focus, and everything we do as a company is geared towards achieving it. This means that we research, develop and provide pharmaceuticals that make a real difference to people’s lives in areas of unmet medical need, such as in central nervous system (CNS) disorders, nephrology and more. We always aim to help people by trying to create products that nobody else has thought of, rather than create more of the same products that already exist in an overcrowded market.

We regard ourselves as a brave and passionate company that is willing to take on challenges that other companies shy away from, such as the search for anti-infectives to treat tuberculosis, many strains of which are drug-resistant and can prove fatal.

At Otsuka, we are willing to take a long-term view when it comes to investing in researching diseases and disorders that are difficult to treat and that can seriously affect people’s lives: for example, schizophrenia or autosomal dominant polycystic kidney disease (ADPKD).

We understand that it can take a decade or longer to come up with the answers and subsequently provide the medicines that can alleviate or prevent suffering, but perseverance is a trait that is found in all our employees. By giving our people time to be curious and take untravelled paths, Otsuka is working today towards creating the solutions for tomorrow to improve the health of millions of people.